Locally advanced cervical cancer
Conditions
Interventions
None listed
Sponsors
Akiko Furusawa
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Age => 20 years. 2) Patients who have received a sufficient explanation of the study and have provided written informed consent based on their own free will. 3) Patients diagnosed with HPV-associated cervical cancer with a clinical stage of IB2 or higher. 4) Patients scheduled to undergo curative surgery or definitive concurrent chemoradiotherapy (CCRT).
Exclusion criteria
Exclusion criteria: 1) Patients who are judged to be inappropriate for participation in the study by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor marker identification rate Detection rate of tumor markers | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficiency and quality of tumor marker candidate extraction from blood Accuracy of tumor marker identification methods and detectable HPV types Change in tumor markers in blood | — |
Contacts
Public ContactFurusawa Akiko
Shizuoka Cancer Center
Outcome results
None listed